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Summary We assess the feasibility of using the MTT assay as a measure of cell viability in chemosensitivity
testing in ovarian malignancy. The assay utilises the conversion of the tetrazolium salt MTT to formazan by
dehydrogenase enzymes in living cells. We show that the optical density of the formazan produced from MTT
is directly proportional to the number of live cells tested. Optimum MTT conversion occured after 4 h
incubation and dimethyl sulphoxide was found to be the most suitable solvent for the formazan. Seventy-five
samples of ascitic fluid and/or solid tumour were collected from 56 patients with FIGO stage III-TV ovarian
adenocarcinoma. Malignant cell suspensions with a viability > 75% were prepared from 95% of ascitic fluid
and 75% of biopsy samples by simple techniques. The effect of cytotoxic drugs was assessed in 91% of
patients included in the study. Variation in drug effect between patients was evident following a 48 h
incubation period and was reproducible. Overall platinum and anthraquinone analogues produced the greater
effect but resistance did occur. Our results mirrored reported clinical response rates. Only one sample tested
against chlorambucil showed any drug effect. As this assay produces results in a high percentage of tests and is
rapid and simple it appears suitable for prospective clinical trials to correlate the in vitro results with in vivo
response.
The selection of effective cytotoxic drug treatment for indi-
vidual patients with cancer may improve survival rates.
Many attempts have been made to develop an in vitro
chemosensitivity test to predict the in vivo response. The drug
effects on various cellular parameters; morphology, inhibition
of cell metabolism, radionucleotide precursor incorporation,
membrane damage and stem cell proliferation have been
assessed. The advantages and disadvantages of these methods
have been widely reviewed (Hill, 1983; Carney & Winkler,
1985; Weisenthal & Lippman, 1985). Short term cultures lost
favour with the introduction of clonogenic assays which
measure the proliferative capacity of tumour stem cells. It
was thought that the inhibition of colony formation by
cytotoxic drugs was the best indicator of tumour sensitivity.
However, interest in short term cultures has recently revived,
as the value of assessing critical damage to essential cellular
functions in both resting and proliferating cells is being
recognised (Weisenthal & Lippman, 1985).
Mosmann (1983) described a new approach to quantitate
mitochondrial dehydrogenase activity first described more
than 30 years ago (Black & Speer, 1954). The intervening
development in semi-automated, microtitre techniques has
made his method rapid and simple. The assay, which mea-
sures the conversion of a tetrazolium salt (MTT) to for-
mazan, has already been successfully applied to drug screen-
ing in cell lines (Alley et al., 1988; Carmichael et al., 1987)
and fresh leukaemic cells (Sargent & Taylor, 1989; Twenty-
man et al., 1989; Pieters et al., 1988). Most chemosensitivity
testing previously carried out in ovarian malignancy used the
clonogenic assay (Alberts et al., 1980; Bertoncello et al.,
1982; Alley & Lieber, 1984). This method is technically
difficult. Short term assays are again gaining favour, being
more simple, testing the total tumour cell population and
yielding results before chemotherapy commences (Weisenthal
& Lippman, 1985). Positive correlation of the results of these
assays with the clinical outcome have already been made in
short term tests (Bird et al., 1988; Sargent & Taylor, 1989)
and therefore validate this type of technique. In this study we
assess the feasibility of using the MTT assay in ovarian
malignancy.
Patients and methods
Ascitic fluid (43) and/or tumour biopsies (32) were obtained
from 56 patients with FIGO stage III-IV moderately to
poorly differentiated ovarian adenocarcinoma at laparotomy
or paracentesis. None of these patients had received any
previous drug or surgical treatment. The samples were kept
sterile and tested within 48 h of collection. Ascitic fluid sam-
ples were washed twice in Hanks balanced salt solution
(HBSS, Flow Laboratories, Rickmansworth) and the cells
resuspended in RPMI 1640 (Flow Laboratories) with 10%
fetal calf serum and 25 IU penicillin and 25 jig ml-' strep-
tomycin. Density gradient centrifugation was used to separ-
ate malignant cells from blood stained samples. Two
methods were used to disaggregate biopsy samples;
mechanical separation by teasing and fine needle aspiration
or if necessary the addition of collagenase as described by
Bertoncello et al. (1982). Once a cell suspension was obtained
these samples were also separated by density gradient cent-
rifugation and washed in HBSS before resuspending in cul-
ture medium as described above. Cell counts were performed
using a haemocytometer and the concentration adjusted to
1 x 106 ml-'. The morphology of the cells was assessed prior
to plating on a cytospin preparation. The number of malig-
nant cells was also determined by immunocytochemistry
using a standard APAAP technique with the monoclonal
antibodies HMFG2 (Oxoid, Basingstoke) and Cam 5.2 (Bec-
ton-Dickinson, Cowley, Oxford). The viability of the cells
was determined by trypan blue dye exclusion.
The relationship of cell numbers to the absorbance of
formazan produced was determined by incubation of a range
of known cell concentrations with MTT for 4h. The op-
timum concentration of MTT and the incubation period to
allow adequate formazan production was also determined.
Drug exposure
Each sample obtained was incubated with up to six different
cytotoxic drugs. Stock solutions were prepared in appropriate
solvents to a concentration of 100 jigml-I (cisplatin, dox-
orubicin, chlorambucil, mitoxantrone) and 1 mg mlh' (carbo-
platin, treosulfan) and stored at - 20°C. The drugs were
tested at four concentrations appropriate to the plasma levels
achieved in vivo (Metcalfe, 1983). These were prepared in
medium from stock solutions immediately before use. Cis-
platin and chlorambucil were used in the range 0.625-5;Lg-
ml- 1; doxorubicin and mitoxantrone 0.1-1 fg ml-': treo-
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sulfan and carboplatin 3.12-50 gml1'. 1001il aliquots of
double strength drug dilution were added to individual wells
of a 96 well flat bottom microtitre plate in quadruplicate.
100 tl of cell suspension (1 x I05 cells per well) were added
to the drugs. Control wells containing cells and medium were
interspersed throughout the plate. Wells containing medium
only were used to blank the spectrophotometer. The cells
were continuously exposed to the drugs during a 48 h incuba-
tion period in an humidified chamber with 5% C02/95% air
at 37°C.
MTTassay
Following incubation the plates were inverted, flicking off the
medium and remaining drugs as previously described (Sar-
gent & Taylor, 1989). Fifty ALl of a 2 mg ml-' solution of
MTT (Sigma, Poole) in HBSS without phenol red were
added to each well and the plates incubated for a further 4 h.
Following this the plates were centrifuged for 5 min at 200g
and reinverted to remove unconverted MTT, leaving the
formazan crystals at the bottom of the well. These crystals
were dissolved in 100 LIl of dimethyl sulphoxide (DMSO) by
agitating on a plate shaker for 10 min. The absorbance of the
wells was measured using a Dynatech plate reader (MR 600)
at wavelength 570 nm. The effect of each drug was deter-
mined by calculating the absorbance of the test wells as a
percentage of the control wells.
Results
Behaviour ofcellsfrom ovarian adenocarcinoma in short term
culture
The prepared cell suspensions contained 83 ± 9% malignant
cells as determined by morphological assessment of all the
cytospin preparations. Using immunocytochemistry, the
number of malignant cells in ten (13%) of the cell suspen-
sions was 73 ± 15%. The immunocytochemistry confinned
the morphological assessment and therefore the simpler tech-
nique was routinely used. The viability of the tested samples
was >75%; this was maintained throughout the test period
as assessed by trypan blue dye exclusion and formazan pro-
duction before and following incubation. Total cell number
and percentage of malignant cells in the control samples did
not change significantly during the 48 h test period. Mitoses
were seen in cytospin preparations ofcontrols both on days 0
and 2. Drug exposure for 2, 4 and 6 days was tested in three
patients. However, as found previously with leukaemia cells
(Sargent & Taylor, 1989) the viability of control cells was
greatly reduced by day 4. An assay duration of 48 h was
therefore chosen.
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Figure 2 The optical density of formazan produced by I x I10
cells with increasing concentrations of MTT at I h (A --A ), 2 h
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Figure I The relationship between cells/well and the optical
density of the formazan produced in two patients (0 r2 = 0.979;
0 r2 = 0.94).
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Figure 3 The absorbence spectrum of formazan dissolved in
DMSO (-0), 1:3 HBSS in DMSO (--0) and 1:2 HBSS
in DMSO (A---A).
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Cell numbers, MTT concentration and duration ofincubation
Figure 1 shows the relationship of cell numbers with for-
mazan production in two patients. It is linear up to 3 x 105
cells. The median OD of control cells at day 2 plated at
1 x 105 cells per well was 0.374, range 0.107-1.51. There was
no correlation between the OD (i.e. the metabolic activity) of
the cells and the number of drugs to which they were sen-
sitive. Incubating I x I05 cells with 100jig MTT for 4 h gave
optimum formazan production (Figure 2).
Solvent
Formazan crystals are soluble in acid alcohol (0.04 N HC1 in
isopropanol) and DMSO. We have previously described the
use of acid alcohol to dissolve formazan crystals produced by
acute myeloid leukaemic cells (Sargent & Taylor, 1989), but
this method is not satisfactory in the assessment of ovarian
adenocarcinoma cells. These crystals could only be dissolved
in acid alcohol by persistent pipetting which required con-
siderable time and effort. They dissolved easily in DMSO,
but as sodium bicarbonate interferes with the optical density
of formazan in this solvent (Twentyman & Luscombe, 1987)
the unconverted MTT in HBSS must be removed. The plates
were therefore centrifuged and re-inverted prior to the addi-
tion of DMSO. The alteration of the absorbence spectrum of
formazan in DMSO by HBSS is shown in Figure 3. The
absorbence peak of the dissolved formazan is 570nm.
Biopsy disaggregation
Collagenase was used in five samples and mechanical disrup-
tion in 26. Cell suspensions were achieved in 29; two could
not be disaggregated. The two methods produced very
different cell viability. Only two samples separated
mechanically had a viability of <70%, however all those
treated enzymatically had a viability < 10%.
Assessment ofcytotoxic drug effect
Chemosensitivity results were obtained from 51 of the 56
patients (91%). Samples from the remaining five patients
were unsuitable for testing: one was contaminated by micro-
organisms (biopsy), two did not contain sufficient malignant
cells (ascitic fluid) and two did not have satisfactory viability
(<70%, biopsy). Overall results were obtained from 63 of
75 samples received, 95% of the ascitic fluid and 75% of the
biopsies.
The effects of drugs varied considerably between patients
(Figure 4). Weisenthal's criteria (total cell survival,
TCS<30% = sensitivity, Weisenthal et al., 1986) for predict-
ing sensitivity in vivo in haematological malignancy was
applied to these samples. Using this, Table I shows the
number of samples sensitive for each drug. A number of
samples were sensitive to the platinum and anthraquinone
derivatives. Minimal cell kill occurred after exposure to
chlorambucil, only one sample showing any degree of sen-
sitivity. Resistance to all the drugs occurred despite no
previous administration of the drugs in vivo. Eighty-five per
cent of the patients were sensitive to at least one drug, the
remaining 15% showing resistance to all drugs tested.
Carboplatin and cisplatin produced a similar cell kill in 31
(67%) of 46 samples but the dose of the former was 10 times
greater (Figure 5); an observation consistent with other
authors when assessing cell line chemosensitivity by clono-
genic assay (Hill 1987). Of 26 samples which were resistant to
cisplatin, five showed sensitivity to carboplatin and of 30
samples resistant to carboplatin, 10 showed sensitivity to
cisplatin.
The effect of doxorubicin was very similar to mitoxantrone
in the equivalent dose range in 77% of samples tested against
both. Of 24 samples which were resistant to doxorubicin, one
was sensitive to mitoxantrone and of 29 resistant to mitoxan-
trone six were sensitive to doxorubicin.
Table I Comparison of cell survival after drug exposure
Number ofpatients (%)
TCS<30% TCS>30%
Drug tsgml-' (Sensitive) (Resistant) Total
Cisplatin 5 26 (43%) 34 60
Carboplatin 50 16 (35%) 30 46
Doxorubicin 1 17 (31%) 37 54
Mitoxantrone 1 6 (17%) 30 36
Treosulfan 50 8 (23%) 27 35
Chlorambucil 5 1 ( 2%) 48 49
TCS, total cell survival.
Table II Reproducibility of the MTT assay in four patients
Drug concentration TCS % (s.e.m.)
Patient (JAgmh-) Assay I Assay 2
DC Cis 0.625 69(13) 73(8)
1.25 57(8) 50(8)
PT Cis 0.625 97(10) 90(10)
1.25 90(4) 90(6)
Dox 0.5 39(3) 35(4)
0.75 18(3) 14(4)
Chl 0.625 93(8) 97(2)
1.25 105(5) 108(5)
AG Cis 0.625 100(10) 76(10)
1.25 84(3) 86(12)
PA Cis 0.625 80(2) 94(7)
1.25 89(7) 87(3)
Dox 0.5 16(2) 28(8)
0.75 12(5) 12(5)
Chl 0.625 110(18) 89(3)
1.25 90(9) 88(13)
Cis, cisplatin; Dox, doxorubicin; Chl, chlorambucil; TCS, total cell
survival.
The reproducibility of the assay is shown in Table II. In
patients DC and PT the assay was performed on two
occasions using the same sample. Two separate samples were
obtained from patients AG and PA; the first at diagnostic
paracentesis and the second at ensuing laparotomy.
Discussion
The aim of these experiments was to assess the feasibility of
using the MUT assay for chemosensitivity testing of individ-
ual patients with ovarian malignancy. We have shown that
the criteria necessary for validation of the MTU assay can be
fulfilled using cells derived from malignant effusions and
biopsy samples from patients with ovarian cancer. Single cell
suspensions with good viability suitable for analysis could be
obtained and required little preparation before drug incuba-
tion. The relatively small number ofcells required, 1-2 x 106
for each drug, allows assessment of a range of concentrations
of many cytotoxic agents. A good, reproducible variation in
drug effect between patients is obtained after only 48 h
incubation. Each patient had an individual drug resistance
and sensitivity pattern. This drug sensitivity profile could
offer the clinician the opportunity to select an active agent in
individual cases. Testing of primary tumour samples has this
obvious advantage but could, however, present some tech-
nical difficulties. Contamination by metabolically active non-
malignant cells capable of reducing MTT to formazan could
falsify results. In our study one sample was contaminated by
micro-organisms but this was easily identified before addition
of MTT as all plates are routinely examined by inversion
microscopy before each step of the assay. Although non-
malignant cells were present, all samples had a high percen-192 J.K. WILSON et al.
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Figure 5 Comparison between drug analogues. Log dose-re-
sponse curves in two patients for: (a) doxorubicin (solid lines)
and mitoxantrone (dotted lines); (b) cisplatin (solid lines) and
carboplatin (dotted lines).
tage of malignant cells. The biopsy samples were of poorly
differentiated tumours and consequently contained a high
ratio of malignant/stromal cells. Lymphocytes were the main
non-malignant contaminant. Their numbers were small and
like other authors we found that their metabolic activity was
low (Pieters et al., 1988; Hongo et al., 1987). Occasional
fibroblasts were seen but in a 48 h culture, plate overgrowth
did not occur. Our friable tumour samples lent themselves to
mechanical disaggregation thus obviating the need for enzy-
matic disaggregation, a method we found disappointing des-
pite previous favourable reports (Courtenay, 1983). Ovarian
cancer cells tend to cluster together in the microtitre plate
wells. These small groups of cells create difficulty in assays
which require direct cell counting. They may also be mis-
interpreted as colonies in clonogenic assays (Bertoncello et
al., 1982). By measuring cellular metabolic function in the
MTT assay these problems are circumvented.
The data presented suggest that drug selection could be
aided in 91% of patients with ovarian cancer. The platinum
derivatives, currently the first line treatment in the manage-
ment of ovarian malignancy, produced the greatest cytotoxic
effect in our test system. The 43% response rate found to
cisplatin is closer to the complete clinical response rate
reported by Wiltshaw et al. (1986) than that of 16% reported
by Welander et al. (1983) using the clonogenic assay. The
cross-resistance pattern between the effects of cisplatin and
carboplatin also agrees with that reported from clinical
observations (Wiltshaw, 1985). The sensitivity rate to chlor-
ambucil, however, is lower than the expected value for com-
plete clinical remission (24% Australian Gynaecological
Oncology Group, 1986; 15% Williams et al., 1985). This may
be due to the in vitro concentration of chlorambucil being
too low. We chose this range .because of peak plasma levels
but perhaps a higher concentration range which shows max-
imum variation between patients as proposed by Bosanquet's
group (Bird et al., 1988) would be more appropriate in this
assay.
As surgery is the mainstay of treatment in early ovarian
cancer (87% 5 year survival FIGO stage la, Dembo et al.,
1979), it is in advanced disease that drug screening offers the
greatest benefits. It is of interest that the decision to com-
mence chemotherapeutic agents in recurrent early disease
may depend on the presence of malignant cells in peritoneal
washings obtained at second look laparoscopy or laparotomy
(Wiltshaw, 1981). Such samples would be ideally suited to
this assay.
The true value of the MTT assay in ovarian malignancy
will only be apparent if the in vitro results predict in vivo
response. In view of the variation in drug effect between
patients, the proximity to clinical response rates, the ease of
testing and high percentage of successful assays, we believe
this method is suitable for such clinical trials.
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